Probing the mechanistic basis for T cell fate decisions (R01)
Probing the mechanistic basis for T cell fate decisions (R01)
批准号:
10088367
负责人:
Michael S Kuhns
金额:
$40.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-08-10 至 2023-01-31
关键词:
AffectAntigen-Presenting CellsArchitectureAttenuatedAutomobile DrivingBehaviorBindingBiological AssayBiomedical EngineeringBiosensorCD3 AntigensCD4 Positive T LymphocytesCRISPR/Cas technologyCell membraneCellular ImmunityCellular biologyComplexCytokine ReceptorsDataDetectionDevelopmentDimerizationEPOR geneEctopic ExpressionEngineeringEnzymesExtracellular DomainFluorescence Recovery After PhotobleachingFluorescence Resonance Energy TransferFrequenciesFundingGoalsHealthHumanITAMImageImmunityImmunotherapeutic agentImpairmentIn SituIn VitroIndividualInstructionLinkMapsMechanicsMediatingMediator of activation proteinMembraneMolecularMolecular MachinesMusPeptide/MHC ComplexPeptidesPhosphorylationPhosphotransferasesPositioning AttributeProteinsReagentRegulatory T-LymphocyteReportingScanningSideSignal TransductionSpecificitySurfaceSurveysSystemT cell responseT-Cell ActivationT-Cell ReceptorT-LymphocyteTestingTherapeuticTransgenic MiceTransmembrane DomainTumor-DerivedWorkbasechimeric antigen receptordesignencryptionexperimental analysisextracellularin vivoinsightintravital imagingmicrobialmutantnovelpathogenic microbereceptorrecruitresponsespatial relationshipsrc-Family Kinasestumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
TITLE: Probing the mechanistic basis for T cell fate decisions.
CD4+ T cells use highly sensitive and specific modular biosensors to survey the body for microbial pathogens
or tumors. The TCR is the chief mediator of this behavior. It surveys the contents of MHC on antigen
presenting cells for peptides (pMHC) derived from microbial pathogens or tumors, and relays pMHC-specific
information across the cell membrane to the ten immunoreceptor tyrosine-based activation motifs (ITAMs) of
the associated CD3γε , CD3δε, and CD3ζζ signaling modules. CD4 recruits Lck to the TCR-CD3 complex upon
concurrent binding of MHC. The quantity and quality of ITAM phosphorylation by Lck provides the base set of
instructions that inform CD4+ T cell fate decision. Yet, how the individual subunits of the TCR-CD3-pMHC-CD4
macro-complex fit and work together to drive CD4+ T cell fate decisions remains to be fully defined. Our
working hypothesis is that these molecules operate on a similar mechanistic principle to less complex receptor
systems, such as cytokine receptors, whereby receptor-associated intracellular signaling enzymes and their
substrates are held in a spatial relationship that represents “off”; pMHC-engagement and reciprocal
extracellular interactions between the TCR-CD3 complex and CD4 then positions the intracellular signaling
domains in the appropriate spatial relationship for a sufficient duration to initiate and potentiate signaling. Our
overarching goal is understand the inner workings of this complex molecular machinery so that we can modify
or imitate its form and function to design novel modular biosensors with unique therapeutic functions. During
the previous funding period we built multiple experimental platforms to study the spatial relationship between
the juxtamembrane (JM) regions of the TCR-CD3 subunits. These allowed us to report the identification of a
mechanical switch that relays pMHC-specific information from the TCR-pMHC interface across the T cell
membrane to the cytosolic juxtamembrane regions of the CD3ζζ signaling module. In addition, we performed
the first experimental analysis of the architecture of the TCR-CD3-pMHC-CD4 macrocomplex and found that
the CD4 JM region is proximal to the CD3 heterodimers, while CD3ζζ resides on the opposite side of the TCR.
We also identified highly conserved residues in the TMD and extracellular domains of CD4 that are important
for CD4's Lck-independent and Lck-dependent functions. Finally, we obtained functional evidence for TCR-
intrinsic specificity for MHC that we interpret as evidence for MHC scanning. The goals for this renewal
application are to deconstruct the molecular mechanisms by which the TCR-CD3-pMHC-CD4 macrocomplex
operates and characterize the consequences of these mechanisms in vivo. Our work will yield fundamental
insights into the key determinants of CD4+ T cell fate decisions and provide a blueprint for the development of
novel modular biosensors with translational potential.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.4049/jimmunol.2200377
发表时间:
2022-11-15
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Kim CY, Parrish HL, Kuhns MS]
通讯作者:
Kuhns MS
DOI:
10.1016/j.immuni.2015.06.018
发表时间:
2015-08-18
期刊:
Immunity
影响因子:
32.4
作者:
[Lee MS, Glassman CR, Deshpande NR, Badgandi HB, Parrish HL, Uttamapinant C, Stawski PS, Ting AY, Kuhns MS]
通讯作者:
Kuhns MS
A Transmembrane Domain GGxxG Motif in CD4 Contributes to Its Lck-Independent Function but Does Not Mediate CD4 Dimerization.
CD4 中的跨膜结构域 GGxxG 基序有助于其 Lck 独立功能,但不介导 CD4 二聚化。
DOI:
10.1371/journal.pone.0132333
发表时间:
2015
期刊:
PloS one
影响因子:
3.7
作者:
[Parrish,HeatherL, Glassman,CalebR, Keenen,MadelineM, Deshpande,NehaR, Bronnimann,MatthewP, Kuhns,MichaelS]
通讯作者:
Kuhns,MichaelS
DOI:
10.1016/j.immuni.2018.11.008
发表时间:
2018
期刊:
Immunity
影响因子:
32.4
作者:
[Lichauco,Katrina, Lee,MarkS, Kuhns,MichaelS]
通讯作者:
Kuhns,MichaelS
Engineering 2nd generation 5MCARs to monitor and treat Type-I Diabetes
-
批准号:10598106
-
项目类别:
-
资助金额:$83.11万
-
财政年份:2022
-
负责人:Michael S Kuhns
-
依托单位:
Engineering and Testing of Biomimetic Stimulators for Therapeutic Applications
-
批准号:10705808
-
项目类别:
-
资助金额:$23.03万
-
财政年份:2022
-
负责人:Michael S Kuhns
-
依托单位:
Adapting 5MCAR technology for the treatment of peripheral T cell lymphoma
-
批准号:10351121
-
项目类别:
-
资助金额:$18.71万
-
财政年份:2022
-
负责人:Michael S Kuhns
-
依托单位:
Adapting 5MCAR technology for the treatment of peripheral T cell lymphoma
-
批准号:10543167
-
项目类别:
-
资助金额:$21.79万
-
财政年份:2022
-
负责人:Michael S Kuhns
-
依托单位:
Engineering 2nd generation 5MCARs to monitor and treat Type-I Diabetes
-
批准号:10435625
-
项目类别:
-
资助金额:$84.17万
-
财政年份:2022
-
负责人:Michael S Kuhns
-
依托单位:
Engineering and Testing of Biomimetic Stimulators for Therapeutic Applications
-
批准号:10570359
-
项目类别:
-
资助金额:$19.19万
-
财政年份:2022
-
负责人:Michael S Kuhns
-
依托单位:
Inducing Tolerance with 5-Module chimeric Antigen Receptor (5MCAR) T Cells
-
批准号:10247395
-
项目类别:
-
资助金额:$77.78万
-
财政年份:2020
-
负责人:Michael S Kuhns
-
依托单位:
Development of Cellular Tools and Techniques to Identify Low Affinity T Cells
-
批准号:10259675
-
项目类别:
-
资助金额:$19.19万
-
财政年份:2020
-
负责人:Michael S Kuhns
-
依托单位:
Development of Cellular Tools and Techniques to Identify Low Affinity T Cells
-
批准号:9974912
-
项目类别:
-
资助金额:$23.03万
-
财政年份:2020
-
负责人:Michael S Kuhns
-
依托单位:
Probing the mechanistic basis for T cell fate decisions (R01)
-
批准号:8702920
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2012
-
负责人:Michael S Kuhns
-
依托单位:
Probing the mechanistic basis for T cell fate decisions (R01)
-
批准号:8527704
-
项目类别:
-
资助金额:$35.6万
-
财政年份:2012
-
负责人:Michael S Kuhns
-
依托单位:
Probing the mechanistic basis for T cell fate decisions (R01)
-
批准号:8883110
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2012
-
负责人:Michael S Kuhns
-
依托单位:
Probing the mechanistic basis for T cell fate decisions (R01)
-
批准号:8343822
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2012
-
负责人:Michael S Kuhns
-
依托单位:
海外基金